ZGN 1061

Drug Profile

ZGN 1061

Alternative Names: ZGN-1061; ZGN1601

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zafgen
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 08 Aug 2017 Zafgen plans a phase II trial for Type 2 diabetes mellitus in Australia and New Zealand in the third quarter of 2017
  • 10 Jun 2017 Preclinical trials in Type-2 diabetes mellitus in USA (SC)
  • 10 Jun 2017 Pharmacokinetics and pharmacodynamic data from a preclinical study in Obesity presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top